secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-10-05T12:00:15+00:00
Accession:  0001104659-26-113503
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rezolute: FDA recommends pre-BLA meeting for ersodetug in congenital HI despite sunRIZE missing primary endpoint
--------------------------------------------------------------------------------

- FDA recommended a Type B pre-BLA meeting as a precursor to a BLA for ersodetug in congenital hyperinsulinism, after reviewing data Rezolute submitted in June 2026.
- sunRIZE Phase 3 missed its primary endpoint: finger-stick SMBG hypoglycemia event reductions were not statistically significant vs placebo; key CGM secondary endpoint at Week 24 also not met.
- FDA explicitly did not opine on approvability of ersodetug for congenital HI, noting any determination would only come during a formal BLA review.
- Topline results from the Phase 3 upLIFT study in tumor HI are expected this quarter; Rezolute will then evaluate BLA strategy for potentially both programs.
- sunRIZE open-label extension ongoing with high retention; ersodetug treatment duration ranges ~9 months to over 2 years, with continued glycemic control and reduced background standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/0001104659-26-113503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/tm2626976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer